Q32 Bio Inc. Common Stock QTTB
Analyst Ratings
- Consensus
- Buy — 7 Buy · 0 Hold · 0 Sell (7 analysts)
- Avg. Price Target
- $36.50 (+341.4% upside)
Key Stats
- Today's Range
- $7.88 – $10.40
- 50-Day Range
- $7.88 – $16.98
- 52-Week Range
- $1.62 – $23.57
- Volume
- 5.25 million shs
- Average Volume
- 772K shs
- Market Cap
- $246.19 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.03%
- Days to Cover
- 1.00
About Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Related Stocks
Compare head-to-head: QTTB vs LLY·QTTB vs JNJ·QTTB vs ABBV·QTTB vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.